New hope for Hard-to-Treat breast cancer: immune cocktails enter trial
NCT ID NCT03971409
First seen Apr 20, 2026 · Last updated Jun 19, 2026 · Updated 8 times
Summary
This phase 2 trial tests whether combining immunotherapy (avelumab) with other drugs can shrink tumors in people with advanced triple-negative breast cancer that has spread or come back. About 145 participants will receive one of several drug combinations, including avelumab plus liposomal doxorubicin, with or without binimetinib, or avelumab plus sacituzumab govitecan. The goal is to see if these combinations improve response rates compared to standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
Georgetown University
Washington D.C., District of Columbia, 20057, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
O'Neal Comprehensive Cancer Center
Birmingham, Alabama, 35294, United States
-
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Baltimore, Maryland, 21218, United States
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Chicago Medicine Comprehensive Cancer Center
Evergreen Park, Illinois, 60805, United States
-
Vanderbilt University Ingram Cancer Center
Nashville, Tennessee, 37232, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
avelumab, liposomal doxorubicin, binimetinib, sacituzumab govitecan
What this could lead to
If successful, this could point toward more effective treatment options for people with advanced triple-negative breast cancer.
What could go wrong
This is an early phase 2 trial with a small number of participants. The drug combinations may not work better than existing treatments and could cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.